New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
17:46 EDTENDPEndo Pharmaceuticals returns Urocidin global rights to Bioniche
Bioniche Life Sciences announced that global rights to Urocidin are being returned to the company from Endo Pharmaceuticals, a subsidiary of Endo Health Solutions (ENDP). On November 5, it was announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer being run by Endo was being discontinued. The trial was not recruiting at the expected rate and, after discussions with the U.S. FDA regarding the clinical trial design, Endo decided to end the trial before its scheduled completion. As a result of this decision, the two companies came to an agreement that a mutually favorable path forward for the product is to return global rights to Bioniche. In exchange for this agreement, Endo will receive a royalty on future revenue.
News For ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
10:01 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTENDPEndo initiated with a Buy at Guggenheim
Subscribe for More Information
October 21, 2014
06:37 EDTENDPEndo pullback brings buying opportunity, says Piper Jaffray
Subscribe for More Information
October 14, 2014
11:23 EDTENDPBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
10:08 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:41 EDTENDPEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information
October 10, 2014
10:01 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:50 EDTENDPEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTENDPAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use